With another set of positive, top-line phase III results for its pain drug BEMA (bioerodible mucoadhesive) buprenorphine, this time for back pain in opioid-experienced patients, Biodelivery Sciences International Inc.'s (BDSI) partner Endo Pharmaceuticals Inc. plans a sit-down with the FDA later this month to talk about a new drug application (NDA).